Agios Pharmaceuticals, Inc. (AGIO) Stock Price & Analysis

Agios Pharmaceuticals, Inc. (AGIO) rose 2.55% to USD 28.14 as of June 10, 2026 at 00:44 UTC, according to Nexqual real-time market data.

AGIO last closed at USD 27.44; the session ranged USD 26.89–28.45 on volume of 1,273,309 shares. Market capitalization is $1.67B, with a 52-week range of USD 22.24–46 (NMS). Source: Nexqual, June 10, 2026 at 00:44 UTC.

Key Statistics (as of June 10, 2026 at 00:44 UTC)

Technical Analysis (AGIO)

Nexqual's technical model rates AGIO "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:44 UTC.

Analyst Ratings (AGIO)

Wall Street analysts rate AGIO "Buy" based on 8 analysts, with a mean price target of USD 40.88 (range USD 28–59), per Nexqual as of June 10, 2026 at 00:44 UTC.

Earnings (AGIO)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:44 UTC.

Financials & Fundamentals (AGIO)

Source: Nexqual, June 10, 2026 at 00:44 UTC.

Financial Health Score (AGIO)

Nexqual rates Agios Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:44 UTC.

Ownership (AGIO)

Source: Nexqual, June 10, 2026 at 00:44 UTC.

Leadership (AGIO)

Agios Pharmaceuticals, Inc. is led by Brian M. Goff (age 56), CEO & Director, per Nexqual as of June 10, 2026 at 00:44 UTC.

Major Backers & Investors (AGIO)

Notable institutional backers of Agios Pharmaceuticals, Inc. include Farallon Capital Management LLC, Armistice Capital, LLC, Erste Asset Management GmbH, according to Nexqual as of June 10, 2026 at 00:44 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:44 UTC.

From Agios Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)

Key Strengths & Strategy (as disclosed to the SEC)

• We will have a pre-supplemental New Drug Application, or sNDA, meeting with the FDA in the first quarter of 2026 and intend to submit a U.S. marketing application for mitapivat in sickle cell disease, or SCD, following that engagement.
• Intellectual Property Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our product candidates and our core technologies, including novel biomarker and diagnostic discoveries, and other know-how, to operate without infringing on the proprietary rights of others and to prevent others from infringing on our proprietary or intellectual property rights.
• We also rely on confidential information, know-how, in-licensing opportunities and continuing technological innovation to develop and maintain our proprietary and intellectual property position.
• We seek to protect our proprietary information, in part, by using confidentiality agreements with our collaborators, third-party service providers, scientific advisors, employees and consultants, and by invention assignment agreements with our employees.

Partnerships

• Revenues associated with the NewBridge Agreement, the Avanzanite Agreement and the for charge portion of our global managed access program are included in the rest of world product revenue line within R esults of O perations .
• Also, in July 2023, we entered into a license agreement with Alnylam for the development and commercialization of products containing or comprised of an siRNA preclinical development candidate discovered by Alnylam and targeting the TMPRSS6 gene, and we are developing a product candidate, AG-236, for the potential treatment of patients with PV.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:44 UTC. This page is informational and not investment advice.